Rechercher
image du produit
Lancet Oncology, The

S'abonner

Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial - 02/06/18

Doi : 10.1016/S1470-2045(18)30195-5 
Rebekka Schäfer, MD a, ⁎ , Vratislav Strnad, ProfMD b, Csaba Polgár, ProfMD c, d, Wolfgang Uter, ProfMD e, Guido Hildebrandt, ProfMD f, h, Oliver J Ott, ProfMD b, Daniela Kauer-Dorner, MD g, Hellen Knauerhase, MD h, Tibor Major, PhD c, Jaroslaw Lyczek, MD i, j, Jose Luis Guinot, MD k, Jürgen Dunst, ProfMD l, Cristina Gutierrez Miguelez, ProfMD m, Pavel Slampa, ProfMD n, Michael Allgäuer, MD o, Kristina Lössl, MD p, György Kovács, ProfMD q, Arnt-René Fischedick, ProfMD r, Rainer Fietkau, ProfMD b, h, Alexandra Resch, ProfMD g, Anna Kulik, MD j, Leo Arribas, ProfMD k, Peter Niehoff, ProfMD l, s, Ferran Guedea, ProfMD m, Annika Schlamann, MD f, Christine Gall, DSc e, Bülent Polat, MD a
on behalf of the

Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO)

Thomas G Wendt, Marion Hindemith, Richard Pötter, Martina Malzer

a Department of Radiation Oncology, University Hospital Würzburg, Würzburg, Germany 
b Department of Radiation Oncology, University Hospital Erlangen, Erlangen, Germany 
c Center of Radiotherapy, National Institute of Oncology, Budapest, Hungary 
d Department of Oncology, Semmelweis University, Budapest, Hungary 
e Department of Medical Informatics, Biometry and Epidemiology, University Erlangen-Nuremberg, Erlangen, Germany 
f Department of Radiation Oncology, University Hospital Leipzig, Leipzig, Germany 
g Department of Radiation Oncology, University Hospital AKH Wien, Vienna, Austria 
h Department of Radiation Oncology, University Hospital Rostock, Rostock, Germany 
i Podkarpacki Hospital Cancer Center Brzozow, Brzozow, Poland 
j Brachytherapy Department, Centrum Onkologii-Instytut im Marii Skłodowskiej, Warsaw, Poland 
k Department of Radiation Oncology, Valencian Institute of Oncology, Valencia, Spain 
l Department of Radiation Oncology, University Hospital Kiel, Kiel, Germany 
m Department of Radiation Oncology, Catalan Institute of Oncology, Barcelona, Spain 
n Department of Radiation Oncology, Masaryk Memorial Cancer Institute and Faculty of Medicine, Brno, Czech Republic 
o Department of Radiation Oncology, Hospital Barmherzige Brüder, Regensburg, Germany 
p Department of Radiation Oncology, University Hospital Bern, Inselspital, Switzerland 
q Interdisciplinary Brachytherapy Unit, University of Lubeck/Universitätsklinikum Schleswig-Holstein Campus Lubeck, Lubeck, Germany 
r Department of Radiation Oncology, Clemens Hospital, Münster, Germany 
s Department of Radiotherapy, Sana Hospital Offenbach, Offenbach, Germany 

* Correspondence to: Dr Rebekka Schäfer, Department of Radiation Oncology, University Hospital Würzburg, 97080 Würzburg, Germany Department of Radiation Oncology University Hospital Würzburg Würzburg 97080 Germany

Summary

Background

Previous results from the GEC-ESTRO trial showed that accelerated partial breast irradiation (APBI) using multicatheter brachytherapy in the treatment of early breast cancer after breast-conserving surgery was non-inferior to whole-breast irradiation in terms of local control and overall survival. Here, we present 5-year results of patient-reported quality of life.

Methods

We did this randomised controlled phase 3 trial at 16 hospitals and medical centres in seven European countries. Patients aged 40 years or older with 0–IIA breast cancer were randomly assigned (1:1) after breast-conserving surgery (resection margins ≥2 mm) to receive either whole-breast irradiation of 50 Gy with a boost of 10 Gy or APBI using multicatheter brachytherapy. Randomisation was stratified by study centre, tumour type, and menopausal status, with a block size of ten and an automated dynamic algorithm. There was no masking of patients or investigators. The primary endpoint of the trial was ipsilateral local recurrence. Here, we present 5-year results of quality of life (a prespecified secondary endpoint). Quality-of-life questionnaires (European Organisation for Research and Treatment of Cancer QLQ-C30, breast cancer module QLQ-BR23) were completed before radiotherapy (baseline 1), immediately after radiotherapy (baseline 2), and during follow-up. We analysed the data according to treatment received (as-treated population). Recruitment was completed in 2009, and long-term follow-up is continuing. The trial is registered at ClinicalTrials.gov, number NCT00402519.

Findings

Between April 20, 2004, and July 30, 2009, 633 patients had accelerated partial breast irradiation and 551 patients had whole-breast irradiation. Quality-of-life questionnaires at baseline 1 were available for 334 (53%) of 663 patients in the APBI group and 314 (57%) of 551 patients in the whole-breast irradiation group; the response rate was similar during follow-up. Global health status (range 0–100) was stable in both groups: at baseline 1, APBI group mean score 65·5 (SD 20·6) versus whole-breast irradiation group 64·6 (19·6), p=0·37; at 5 years, APBI group 66·2 (22·2) versus whole-breast irradiation group 66·0 (21·8), p=0·94. The only moderate, significant difference (difference of 10–20 points) between the groups was found in the breast symptoms scale. Breast symptom scores were significantly higher (ie, worse) after whole-breast irradiation than after APBI at baseline 2 (difference of means 13·6, 95% CI 9·7–17·5; p<0·0001) and at 3-month follow-up (difference of means 12·7, 95% CI 9·8–15·6; p<0·0001).

Interpretation

APBI with multicatheter brachytherapy was not associated with worse quality of life compared with whole-breast irradiation. This finding supports APBI as an alternative treatment option after breast-conserving surgery for patients with early breast cancer.

Funding

German Cancer Aid.

Le texte complet de cet article est disponible en PDF.

Plan


© 2018  Elsevier Ltd. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

    •

  • Contenu

    •

Vol 19 - N° 6

P. 834-844 - juin 2018 Retour au numéro
Article précédent Article précédent
  • [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
  • Michael S Hofman, John Violet, Rodney J Hicks, Justin Ferdinandus, Sue Ping Thang, Tim Akhurst, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Declan G Murphy, Peter Eu, Price Jackson, Mark Scalzo, Scott G Williams, Shahneen Sandhu
| Article suivant Article suivant
  • Gut dysbiosis: a potential link between increased cancer risk in ageing and inflammaging
  • Arya Biragyn, Luigi Ferrucci

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.

Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.